Treatment Characteristics for Nonmetastatic Castration-Resistant Prostate Cancer in the United States, Europe and Japan

References

• American Cancer Society . Key statistics in prostate cancer (2019). https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
   Google Scholar
• Mohler JL . The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J. Natl Compr. Canc. Netw.8(2), 162–200 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang TY , AgarwalN, SonpavdeG, DilorenzoG, BellmuntJ, VogelzangNJ. Management of castrate resistant prostate cancer – recent advances and optimal sequence of treatments. Curr. Urol. Rep.14(3), 174–183 (2013).
   PubMed Web of Science ®Google Scholar
• Hotte SJ , SaadF. Current management of castrate-resistant prostate cancer. Curr. Oncol.17(Suppl. 2), S72 (2010).
   PubMed Web of Science ®Google Scholar
• Kantoff PW , HiganoCS, ShoreNDet al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Tombal B . Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?Ann. Oncol.23(Suppl. 10), x251–x258 (2012).
   PubMed Web of Science ®Google Scholar
• Beaver JA , KluetzPG, PazdurR. Metastasis-free survival – a new end point in prostate cancer trials. N. Engl. J. Med.378(26), 2458–2460 (2018).
   PubMed Web of Science ®Google Scholar
• Gillessen S , AttardG, BeerTMet al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur. Urol.73(2), 178–211 (2018).
   PubMed Web of Science ®Google Scholar
• Dall’era MA , AlbertsenPC, BangmaCet al. Active surveillance for prostate cancer: a systematic review of the literature. Eur. Urol.62(6), 976–983 (2012).
   PubMed Web of Science ®Google Scholar
• European Society for Medical Oncology . FDA broadens approval for enzalutamide to include non-metastatic castration-resistant prostate cancer (2018). www.esmo.org/Oncology-News/FDA-Broadens-Approval-for-Enzalutamide-to-Include-Non-Metastatic-Castration-Resistant-Prostate-Cancer
   Google Scholar
• Astellas . Astellas receives european approval for XTANDI™ (enzalutamide) for adult men with high-risk non-metastatic castration-resistant prostate cancer (2018). www.astellas.com/en/news/14311
   Google Scholar
• Yamasaki M , YuasaT, YamamotoSet al. Efficacy and safety profile of enzalutamide for japanese patients with castration-resistant prostate cancer. Anticancer Res.36(1), 361–365 (2016).
   PubMed Web of Science ®Google Scholar
• Johnson&Johnson . Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease (2018). www.jnj.com/janssen-receives-positive-chmp-opinion-for-erleada-apalutamide-for-patients-with-non-metastatic-castration-resistant-prostate-cancer-who-are-at-high-risk-of-developing-metastatic-disease
   Google Scholar
• Latif MF , TirmazySH, HussainSA, JacksonR, BarnettC, AzamF. Management of non metastatic castrate resistant prostate cancer (NM-CRPC), results of a UK wide national survey. J. Clin. Oncol.34(Suppl. 15), e16520–e16520 (2016).
   Google Scholar
• Pokras SM , ZyczynskiTM, LeesM, JiaoX, BlanchetteC, PowersJ. Treatment patterns after castration resistant prostate cancer (CRPC) diagnosis: a European physician survey. Value Health16(3), A1 (2013).
   PubMed Web of Science ®Google Scholar
• Caldeira R , ScazafaveM. Real-world treatment patterns for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in Europe and the United States. Oncol. Ther.4(2), 189–197 (2016).
   PubMedGoogle Scholar
• Varghese D , HillK, BottemanM. Functional status and associated treatment patterns among metastatic triple negative breast cancer (mTNBC) in EU 5. Eur. J. Cancer92, S118–S119 (2018).
   Web of Science ®Google Scholar
• Karki C , PatelR, MartinoS, WriedeV, Shah-ManekB. Treatment pattern differences across the United States and EU5 among patients with ovarian cancer (2018). https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e17516
   Google Scholar
• Ysebaert L , PhilipB, StilgenbauerS. Real-world treatment patterns of rituximab usage as single-agent therapy or part of combination regimens in chronic lymphocytic leukemia (CLL) in Eu5 countries (UK, France, Germany, Italy, and Spain). Value Health17(3), A234 (2014).
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) Foundation . NCCN guidelines for patients 2018 – prostate cancer (2018). www.nccn.org/patients/guidelines/prostate/files/assets/common/downloads/files/prostate.pdf
   Google Scholar
• American Cancer Society . Watchful waiting or active surveillance for prostate cancer (2016). www.cancer.org/cancer/prostate-cancer/treating/watchful-waiting.html
   Google Scholar
• Parker C , GillessenS, HeidenreichA, HorwichA, ESMO Guidelines Committee. Cancer of the prostate: ESMO clinical practice guidelines. Ann. Oncol.26(5), 69–77 (2015).
   PubMedGoogle Scholar
• Kakehi Y , SugimotoM, TaokaR, Committee for Establishment of the Evidenced-Based Clinical Practice Guideline for Prostate Cancer of the Japanese Urological Association. Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Inter. J. Urol24(9), 648–666 (2017).
   PubMed Web of Science ®Google Scholar
• Kinsella N , HellemanJ, BruinsmaSet al. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl. Androl. Urol.7(1), 83–97 (2018).
   PubMed Web of Science ®Google Scholar
• American Cancer Society . Initial treatment of prostate vancer, by stage (2016). http://www.cancer.org/cancer/prostate-cancer/treating/by-stage.html
   Google Scholar
• Smith MR , SaadF, ChowdhurySet al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med.378(15), 1408–1418 (2018).
   PubMed Web of Science ®Google Scholar
• Hussain M , FizaziK, SaadFet al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med.378(26), 2465–2474 (2018).
   PubMed Web of Science ®Google Scholar
• Srinivas S , MohamedAF, AppukkuttanSet al. Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC). J. Clin. Oncol. (2019). https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e16610
   PubMedGoogle Scholar
• Sternberg CN , Baskin-BeyES, WatsonM, WorsfoldA, RiderA, TombalB. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer. BMC Urol.13, 58 (2013).
   PubMed Web of Science ®Google Scholar
• Engel-Nitz NM , AlemayehuB, ParryD, NathanF. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag. Res.3, 233–245 (2011).
   PubMedGoogle Scholar
• Mateo J , FizaziK, GillessenSet al. Managing nonmetastatic castration-resistant prostate cancer. Eur. Urol.75(2), 285–293 (2018).
   PubMed Web of Science ®Google Scholar
• Astellas . Astellas submits supplemental new drug application for approval of additional Indication of XTANDI® for the treatment of men with metastatic hormone-sensitive prostate cancer in Japan (2019). www.astellas.com/en/news/14851
   Google Scholar
• Cheung S , HamuroY, MahlichJ, NakayamaM, TsubotaA. Treatment pathways of Japanese prostate cancer patients – a retrospective transition analysis with administrative data. PLoS ONE13(4), e0195789 (2018).
   PubMed Web of Science ®Google Scholar
• Lowrance WT , MuradMH, OhWK, JarrardDF, ResnickMJ, CooksonMS. Castration-resistant prostate cancer: AUA guideline amendment 2018. J. Urol.200(6), 1264–1272 (2018).
   PubMed Web of Science ®Google Scholar
• Flaig TW , PotluriRC, NgY, ToddMB, MehraM. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med.5(2), 182–191 (2016).
   PubMed Web of Science ®Google Scholar
• Uemura H , DibonaventuraM, WangE, LedesmaDA, ConcialdiK, AitokuY. The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use. Expert Rev. Pharmacoecon. Outcomes Res.17(5), 511–517 (2017).
   PubMed Web of Science ®Google Scholar
• US FDA . FDA approves apalutamide for non-metastatic castration-resistant prostate cancer (2018). www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm596796.htm
   Google Scholar
• European Pharmaceutical Review . European Commission approves prostate cancer treatment Erleada (2019). www.europeanpharmaceuticalreview.com/news/83107/european-commission-prostate-cancer/
   Google Scholar
• Fizazi K , ShoreN, TammelaTLet al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med.380(13), 1235–1246 (2019).
   PubMed Web of Science ®Google Scholar